Compare DTE & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTE | GEHC |
|---|---|---|
| Founded | 1903 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 33.1B |
| IPO Year | N/A | N/A |
| Metric | DTE | GEHC |
|---|---|---|
| Price | $128.80 | $84.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $149.36 | $86.67 |
| AVG Volume (30 Days) | 1.4M | ★ 4.2M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.59% | 0.17% |
| EPS Growth | N/A | ★ 32.35 |
| EPS | ★ 6.67 | 4.83 |
| Revenue | $14,822,000,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $10.64 | $6.33 |
| Revenue Next Year | $4.66 | $4.38 |
| P/E Ratio | $19.46 | ★ $17.38 |
| Revenue Growth | ★ 19.39 | 3.51 |
| 52 Week Low | $116.30 | $57.65 |
| 52 Week High | $143.79 | $94.80 |
| Indicator | DTE | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 30.73 | 62.47 |
| Support Level | $129.53 | $83.56 |
| Resistance Level | $132.11 | $86.19 |
| Average True Range (ATR) | 1.96 | 2.22 |
| MACD | -0.35 | 0.36 |
| Stochastic Oscillator | 7.68 | 78.87 |
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).